Caption
These include ACLY, ACC, and FASN, regulated by transcription factor SREBP1c. In HCC, SREBP1c can be overexpressed by P13K/Akt/mTOR pathway activated by CD147 and its downstream molecules, such as FOXO1, GSK3, and LPIN1. Hyperlipidemia triggers the release of FGL1, which is a suppressor of the Akt/mTOR pathway. On the other hand, beta-oxidation can be suppressed by inhibiting the p38/MAPKs/PPARα/CPT1A/ACOX1 pathway mediated by CD147. In regenerative cells, HNF-1α and phosphorylated STAT3 can upregulate FGL1, triggering proliferative pathways like EGFR/Src/ERK. Nonetheless, in HCC, deletion of HNF-1α downregulates FGL1 promoter, which in turn reduces the secretion of SREBP. Under hypoxic conditions, the JAK2/STAT3 pathway induces HIF-1α, which inhibits beta-oxidation by inhibiting mitochondrial enzymes like MCAD and LCAD. ACC, acetyl-CoA carboxylase; ACOX1, acyl-CoA oxidase 1; AKT, Ak strain transforming; ACL, ATP-citrate lyase; CPT1A, carnitine palmitoyltransferase I; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; FASN, fatty acid synthase; FGL1, fibrinogen-like protein 1; FOXO1, forkhead box protein O1; GP130, glycoprotein 130; GSK3, glycogen-synthase kinase-3; HIF-1α, hypoxia-inducible factor-1 alpha; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HNF-1α, hepatocyte nuclear factor-1 alpha; IL6-R, interleukin-6 receptor; JAK2, Janus kinase 2; LDLR, low-density lipoprotein receptor; LCAD, long-chain acyl-CoA dehydrogenase; MAPKs, mitogen-activated protein kinases; MCAD, medium-chain acyl-CoA dehydrogenase; MEK, mitogen-activated ERK kinase; MUFAs, monounsaturated fatty acids; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-3-kinase; PPARα, peroxisome proliferator-activated receptor alpha; RAS, rat sarcoma; SCD, stearoyl-CoA desaturase; SREBP1c, sterol regulatory element-binding protein 1c; STAT3, signal transducer and activator of transcription 3.